Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(34 sites)
United States
California Cancer Associates for Research and Excellence, Encinitas, California University of California San Diego UCSD, La Jolla, California UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California Hoag - Huntington Beach, Newport Beach, California Regents of the University of Colorado, Aurora, Colorado Sarah Cannon Research Institute at HealthONE, Denver, Colorado Massachusetts General Hospital, Boston, Massachusetts Karmanos Cancer Insitute, Detroit, Michigan Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada Stony Brook University, Stony Brook, New York SCRI Oncology Partners - Nashville, Nashville, Tennessee NEXT Oncology Virginia, Fairfax, Virginia Fred Hutchinson Cancer Center, Seattle, Washington Belgium
Institut Jules Bordet, Anderlecht UZ Leuven - Campus Gasthuisberg, Leuven GZA Hopsitals Campus Sint-Augustinus, Wilrijk France
Centre de Lutte Contre le Cancer CLCC - Centre Georges Francois Leclerc (CGFL), Dijon Centre Oscar Lambret, Lille Centre Antoine Lacassagne, Nice Hopital Lyon Sud, Pierre-Bénite Institut Gustave Roussy, Villejuif Italy
Ospedale San Raffaele, Milan Ospedale San Gerardo-ASST Monza, Monza Istituto Clinico Humanitas, Rozzano South Korea
Gachon University Gil Medical Center, Incheon Seoul National University Hospital, Seoul Severance Hospital, Seoul Asan Medical Center, Seoul Samsung Medical Center, Seoul Spain
NEXT Oncology Phase I Unit / IOB- Hospital Quironsalud Barcelona, Barcelona Hospital Beata Maria Ana, Madrid Hospital Universitario 12 de Octubre, Madrid